Dronedarone — Discount Pricing

Other medications in Heart & Cardiovascular

• Empagliflozin (HF)
• Enalapril
• Eplerenone
• Epoprostenol
• Eprosartan
• Evolocumab
• Ezetimibe
• Felodipine

About Dronedarone

Dronedarone is a medication prescribed to help manage atrial fibrillation (AFib), a common heart rhythm disorder. If you've been prescribed dronedarone, you know that managing chronic conditions can be costly. TheDrugClub is dedicated to helping members like you find significant savings on vital prescriptions, including dronedarone.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Dronedarone is approved for (FDA label)

MULTAQ ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14) ] . MULTAQ is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF ( 1 , 14 ).

Source: Read the full FDA label on DailyMed. Label effective date: January 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Dronedarone (FDA label)

WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure, MULTAQ doubles the risk of death [see Clinical Studies (14.3) ] . MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure [see Contraindications (4) , Warnings and Precautions (5.1) ] . In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure [see Clinical Studies (14.4) ] . MULTAQ is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm [see Contraindications (4) , Warnings and Precautions (5.2) ] . WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION See full prescribing information for complete boxed warning. MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure. MULTAQ doubles the risk of death in these patients. ( 4 , 5.1 , 14.3 ) MULTAQ is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm. In patients with permanent AF, MULTAQ doubles the risk of death, stroke, and hospitalization for heart failure. ( 4 , 5.2 , 14.4 )

Source: FDA prescribing information (DailyMed). Set ID: 3bd4006a-8bad-4909-ac6d-b6d84390155c. SPL document ID: 913e2175-cc98-4f39-8941-1a46cc80b888. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Dronedarone (FDA label)

MULTAQ 400 mg tablets are provided as white film-coated tablets for oral administration, oblong-shaped, engraved with a double wave marking on one side and "4142" code on the other side. 400 mg film-coated tablets ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3bd4006a-8bad-4909-ac6d-b6d84390155c. SPL document ID: 913e2175-cc98-4f39-8941-1a46cc80b888. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Dronedarone (FDA label)

The following safety concerns are described elsewhere in the label: • New or worsening heart failure [see Warnings and Precautions (5.4) ] • Liver Injury [see Warnings and Precautions (5.5) ] • Pulmonary toxicity [see Warnings and Precautions (5.6) ] • Hypokalemia and hypomagnesemia with potassium-depleting diuretics [see Warnings and Precautions (5.7) ] • QT prolongation [see Warnings and Precautions (5.8) ] Most common adverse reactions (≥2%) are diarrhea, nausea, abdominal pain, vomiting, dyspepsia, bradycardia, skin issues (rashes, pruritus, eczema, dermatitis, dermatitis allergic), and asthenia ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience The safety evaluation of dronedarone 400 mg twice daily in patients with AF or AFL is based on 5 placebo-controlled studies, ATHENA, EURIDIS, ADONIS, ERATO and DAFNE. In these studies, a total of 6285 patients were randomized and treated, 3282 patients with MULTAQ 400 mg twice daily, and 2875 with placebo.

Source: FDA prescribing information (DailyMed). Set ID: 3bd4006a-8bad-4909-ac6d-b6d84390155c. SPL document ID: 913e2175-cc98-4f39-8941-1a46cc80b888. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Dronedarone (FDA label)

MULTAQ is contraindicated in patients with: • Permanent atrial fibrillation (patients in whom normal sinus rhythm will not or cannot be restored) [see Boxed Warning , Warnings and Precautions (5.2) ] • Symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV symptoms [see Boxed Warning , Warnings and Precautions (5.1) ] • Second or third-degree atrioventricular (AV) block, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker) • Bradycardia <50 bpm • Concomitant use of strong CYP3A inhibitors, such as ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, and ritonavir [see Drug Interactions (7.2) ] • Concomitant use of erythromycin [see Clinical Pharmacology (12.3) ]

Source: FDA prescribing information (DailyMed). Set ID: 3bd4006a-8bad-4909-ac6d-b6d84390155c. SPL document ID: 913e2175-cc98-4f39-8941-1a46cc80b888. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Dronedarone (FDA label)

• Determine cardiac rhythm at least once every 3 months. If AF is detected discontinue MULTAQ or cardiovert. ( 5.2 ) • Ensure appropriate antithrombotic therapy prior to and throughout MULTAQ use. ( 5.3 ) • Liver injury: If hepatic injury is suspected, discontinue MULTAQ. ( 5.5 ) • If pulmonary toxicity is confirmed, discontinue treatment. ( 5.6 ) • Hypokalemia and hypomagnesemia: Maintain potassium and magnesium levels within the normal range. ( 5.7 ) • Renal impairment: Monitor renal function periodically. ( 5.9 ) • Embryofetal Toxicity: Based on animal data, MULTAQ may cause fetal harm when administered to a pregnant woman.

Source: FDA prescribing information (DailyMed). Set ID: 3bd4006a-8bad-4909-ac6d-b6d84390155c. SPL document ID: 913e2175-cc98-4f39-8941-1a46cc80b888. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Dronedarone (FDA label)

Dronedarone is metabolized by CYP3A and is a moderate inhibitor of CYP3A and CYP2D6 and has potentially important pharmacodynamic interactions ( 7 ) • Class I or III antiarrhythmics: Contraindicated. ( 4 , 7.1 ) • Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor digoxin levels. ( 7.1 , 7.3 ) • Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability. ( 7.1 , 7.2 , 7.3 ) • Beta-blockers: May provoke excessive bradycardia. Initiate with low dose and increase after ECG verification of tolerability. ( 7.1 , 7.3 ) • CYP3A inducers: Avoid concomitant use. ( 7.2 ) • Grapefruit juice: Avoid concomitant use. ( 7.2 ) • Statins: Avoid simvastatin doses greater than 10 mg daily.

Source: FDA prescribing information (DailyMed). Set ID: 3bd4006a-8bad-4909-ac6d-b6d84390155c. SPL document ID: 913e2175-cc98-4f39-8941-1a46cc80b888. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.